Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants

Part of paid clinical trials in Overland Park, Kansas.

Sponsor: Deciphera Pharmaceuticals, LLC
Study ID: NCT07744802
Phase: PHASE1
Status: Recruiting

Apply to this trial

Conditions

Healthy Male Participants

Eligibility Criteria

Sex: MALE
Age: 18 Years - 55 Years
Healthy Volunteers: Accepted

Interventions

Vimseltinib — DRUG
Administered orally
Dabigatran — DRUG
Administered orally

Study Details

The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of P-glycoprotein (P-gp) substrate (dabigatran) in healthy male participants. This study will last approximately 21 days.

Key Dates

First listed: Aug 4, 2026
Start date: Sep 30, 2026
Status verified: Sep 2026
Primary completion: Dec 31, 2026
Completion: Dec 31, 2026

Study Design

Enrollment: 20 participants (estimated)
Allocation: NA
Intervention model: SEQUENTIAL
Primary purpose: BASIC_SCIENCE

Arms

Experimental: Vimseltinib + Dabigatran
Day 1 single dose of dabigatran, and Day 5 coadministration of dabigatran with vimseltinib.

Primary Outcome Measure

Pharmacokinetics (PK): Maximum Observed Plasma Drug Concentration (Cmax) of Dabigatran [ Time Frame: Predose up to 48 Hours Post Dose ]

Central Contacts

Clinical Team
888-724-3274
[email protected]

Locations (1)

Facility	City	State	ZIP	Site coordinators
Dr. Vince Clinical Research	Overland Park	Kansas	66212	913-333-3000 Benjamin T Sundling, D.O. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Overland Park, KS

By research site

Dr. Vince Clinical Research· Overland Park, KS